Wellomics™ partners with leading brands to provide proprietary technologies that increase return on investment for R&D, necessary for a new paradigm of personalized evidence-based wellness. By leveraging our 200+ years of diverse expertise, we collaborate with our strategic partners using our “catalyst” discovery process to meet both business and consumer needs. We have created a proprietary, big data network biology system to exploit global research on the biochemosphere™ as well as collective findings from human life sciences to rationally identify optimal combinations of ingredients. Market research and proprietary formulation technologies are utilized to ensure brand differentiation and maximize bioavailability. Licensed formulations include complete documentation necessary for FDA and FTC compliance and lot reproducibility at partners’ manufacturing facilities or qualified CMOs. We also offer validation studies (preclinical, clinical) using state-of-the-art omics technologies, crowdsourcing of efficacy/safety outcomes, and clinical study services to support NDI, self-affirmed GRAS, and label claims. We create products that can be evaluated using devices, biochemical tests, genomic data (e.g. SNPs), and other direct-to-consumer outcomes testing technologies that represent the future of personalized evidence-based wellness.
Looking for a particular Wellomics, LLC employee's phone or email?
The Wellomics, LLC annual revenue was $1 million in 2026.
Aranka Matolcsy is the Owner of Wellomics, LLC.
1 people are employed at Wellomics, LLC.
Wellomics, LLC is based in Bethel, Maine.
The NAICS codes for Wellomics, LLC are [3254, 325, 32541, 32].
The SIC codes for Wellomics, LLC are [283, 28].